Effect of eplerenone on serum level of soluble growth-stimulating receptor expressed by gene 2 in patients with arterial hypertension

Thumbnail Image

Date

2022

Authors

Bilovol, O.
Knyazkova, I.
Golovacheva, V.
Kuzminova, N.
Barbashova, V.
Molodan, D.
Bogun, N.

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

The purpose of the work was to study the dynamics of diastolic function parameters, the content of the soluble growth-stimulating receptor expressed by gene 2 (sST2) and the N-terminal fragment of the brain natriuretic propeptide (NT-proBNP) in the blood of patients with hypertension, when eplerenone is added to antihypertensive therapy. In patients with stage 2 arterial hypertension, addition of eplerenone to antihypertensive therapy contributes to a more pronounced decrease of blood pressure measured by patients during self-monitoring; during daily monitoring compared to antihypertensive therapy. The inclusion of the selective aldosterone mineralocorticoid receptor antagonist eplerenone in the complex therapy of patients with stage 2 arterial hypertension has a pronounced positive effect on the structural and geometric indicators of the myocardium, parameters of the diastolic function of the left ventricle, as well as the content of sST2 and NT-proBNP in the blood serum, along with good tolerability.

Description

Keywords

hypertension, eplerenone, diastolic dysfunction, echocardiography, soluble growth-stimulating receptor expressed by gene 2,N-terminal fragment of brain natriuretic propeptide

Citation

Effect of eplerenone on serum level of soluble growth-stimulating receptor expressed by gene 2 in patients with arterial hypertension / O. M. Bilovol, I. I. Knyazkova, V. O. Golovacheva, N. V. Kuzminova, V. O. Barbashova, D. V. Molodan, M. V. Bogun // World of Medicine and Biology. – 2022. – № 3 (81). – P. 26–31. – DOI: 10.26724/2079-8334-2022-3-81-26-31.

Endorsement

Review

Supplemented By

Referenced By